Eli Lilly’s Stock Performance in September



About Eli Lilly and Company

Eli Lilly and Company (LLY) is a leading pharmaceutical company focused on discovering, developing, manufacturing, and marketing human pharmaceuticals and animal healthcare products.

Eli Lilly stock reported a ~0.6% rise to close at $106.31 on September 26 compared to the previous day’s close.

The chart above compares the changes in analysts’ recommendations for Eli Lilly since January.

Article continues below advertisement

Eli Lilly’s stock performance

Eli Lilly stock has risen a marginal ~0.6% to date in September, while it’s risen nearly 1.1% in the last month.

Eli Lilly has also reported a 26.3% rise in its stock price over the last 12 months and a 25.9% rise in its stock price year-to-date.

However, analysts’ estimates show that the stock could fall ~6.4% over the next 12 months. Analysts’ recommendations show a 12-month target price of $99.53 per share compared to its price of $106.31 per share on September 26.

Analysts’ ratings

On September 27, there were 16 analysts tracking Eli Lilly. Of these, two have recommended “strong buys,” six have recommended “buys,” and eight have recommended “holds.” No analysts have recommended “sells.”

The consensus rating for Eli Lilly and Company stands at 2.38, which represents a moderate “buy” for long-term growth investors as well as value investors. It has been observed that the changes in analysts’ estimates and recommendations are based on the changing trends in a company’s stock price and performance.

The iShares Core High Dividend ETF (HDV) holds 1.6% of its total investments in Eli Lilly, 2.0% in Bristol-Myers Squibb (BMY), 3.8% in Merck & Co. (MRK), and 7.2% in Johnson & Johnson (JNJ).


More From Market Realist